Octagon Capital Advisors
Latest statistics and disclosures from Octagon Capital Advisors's latest quarterly 13F-HR filing:
- Top 5 stock holdings are ABVX, DNTH, COGT, TSHA, GOSS, and represent 45.76% of Octagon Capital Advisors's stock portfolio.
- Added to shares of these 10 stocks: CGON (+$25M), ALMS (+$25M), PALI (+$23M), BIOA (+$21M), RAPT (+$19M), LXEO (+$17M), KYMR (+$14M), EVMN (+$8.6M), DTIL (+$8.0M), MNMD.
- Started 8 new stock positions in ALMS, DTIL, CGON, EVMN, BIOA, LXEO, PALI, RAPT.
- Reduced shares in these 10 stocks: ABVX (-$77M), CDTX (-$44M), MRUS (-$29M), APLS (-$20M), COGT (-$19M), NUVB (-$9.7M), GOSS (-$9.7M), DBVT (-$8.5M), MAZE, NGNE.
- Sold out of its positions in APLS, MAZE, NGNE, NUVB, NUVB.WS, GPCR, MRUS.
- Octagon Capital Advisors was a net seller of stock by $-74M.
- Octagon Capital Advisors has $824M in assets under management (AUM), dropping by 24.85%.
- Central Index Key (CIK): 0001839435
Tip: Access up to 7 years of quarterly data
Positions held by Octagon Capital Advisors consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Octagon Capital Advisors
Octagon Capital Advisors holds 27 positions in its portfolio as reported in the December 2025 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Abivax Sa Sponsored Ads (ABVX) | 12.4 | $102M | -42% | 756k | 134.85 |
|
| Dianthus Therapeutics (DNTH) | 12.1 | $100M | 2.4M | 41.21 |
|
|
| Cogent Biosciences (COGT) | 10.1 | $84M | -18% | 2.4M | 35.52 |
|
| Taysha Gene Therapies Com Shs (TSHA) | 5.9 | $49M | -2% | 8.9M | 5.50 |
|
| Gossamer Bio (GOSS) | 5.2 | $43M | -18% | 14M | 3.10 |
|
| Kymera Therapeutics (KYMR) | 5.1 | $42M | +48% | 535k | 77.81 |
|
| Arrivent Biopharma (AVBP) | 4.8 | $40M | 2.0M | 20.12 |
|
|
| Trevi Therapeutics (TRVI) | 4.3 | $35M | 2.8M | 12.52 |
|
|
| Ocular Therapeutix (OCUL) | 3.9 | $32M | 2.6M | 12.14 |
|
|
| Mind Medicine Mindmed Com New (MNMD) | 3.6 | $30M | +4% | 2.2M | 13.39 |
|
| Cg Oncology Call Option (CGON) | 3.0 | $25M | NEW | 600k | 41.52 |
|
| Alumis (ALMS) | 3.0 | $25M | NEW | 2.5M | 9.76 |
|
| Palisade Bio (PALI) | 2.7 | $23M | NEW | 9.6M | 2.35 |
|
| Cidara Therapeutics Com New (CDTX) | 2.7 | $22M | -66% | 100k | 220.89 |
|
| Bioage Labs (BIOA) | 2.6 | $21M | NEW | 1.6M | 13.23 |
|
| Kalvista Pharmaceuticals (KALV) | 2.5 | $21M | 1.3M | 16.15 |
|
|
| Rapt Therapeutics Com New (RAPT) | 2.4 | $19M | NEW | 574k | 33.87 |
|
| Centessa Pharmaceuticals Sponsored Ads (CNTA) | 2.3 | $19M | -9% | 750k | 25.01 |
|
| Pharvaris N V (PHVS) | 2.3 | $19M | -7% | 672k | 27.75 |
|
| Lexeo Therapeutics (LXEO) | 2.1 | $17M | NEW | 1.7M | 9.93 |
|
| Bridgebio Oncology Therapeut Com New (BBOT) | 1.6 | $13M | 1.0M | 12.52 |
|
|
| Dbv Technologies S A Sponsored Ads (DBVT) | 1.3 | $11M | -43% | 574k | 19.17 |
|
| Evommune Com Shs (EVMN) | 1.0 | $8.6M | NEW | 500k | 17.12 |
|
| Precision Biosciences Com New (DTIL) | 1.0 | $8.0M | NEW | 1.9M | 4.16 |
|
| Corbus Pharmaceuticals Hldgs Com New (CRBP) | 0.9 | $7.8M | -14% | 955k | 8.14 |
|
| Unicycive Therapeutics Com New (UNCY) | 0.7 | $5.8M | 1.0M | 5.77 |
|
|
| Pepgen (PEPG) | 0.6 | $4.6M | 700k | 6.51 |
|
Past Filings by Octagon Capital Advisors
SEC 13F filings are viewable for Octagon Capital Advisors going back to 2020
- Octagon Capital Advisors 2025 Q4 filed Feb. 17, 2026
- Octagon Capital Advisors 2025 Q3 filed Nov. 14, 2025
- Octagon Capital Advisors 2025 Q2 filed Aug. 14, 2025
- Octagon Capital Advisors 2025 Q1 restated filed May 16, 2025
- Octagon Capital Advisors 2025 Q1 filed May 15, 2025
- Octagon Capital Advisors 2024 Q4 filed Feb. 14, 2025
- Octagon Capital Advisors 2024 Q3 filed Nov. 14, 2024
- Octagon Capital Advisors 2024 Q2 filed Aug. 14, 2024
- Octagon Capital Advisors 2024 Q1 filed May 15, 2024
- Octagon Capital Advisors 2023 Q4 filed Feb. 14, 2024
- Octagon Capital Advisors 2023 Q3 filed Nov. 14, 2023
- Octagon Capital Advisors 2023 Q2 filed Aug. 14, 2023
- Octagon Capital Advisors 2023 Q1 filed May 15, 2023
- Octagon Capital Advisors 2022 Q4 filed Feb. 14, 2023
- Octagon Capital Advisors 2022 Q3 filed Nov. 14, 2022
- Octagon Capital Advisors 2022 Q2 filed Aug. 15, 2022